期刊
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
卷 98, 期 -, 页码 41-50出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.ijid.2020.06.022
关键词
Beta-lactam; Extended infusion; Respiratory; Critically ill; Mortality
Objectives: Alternative dosing strategies for beta-lactams - the most common antibiotics used to treat critically ill patients with respiratory tract infections - have been recommended to maximize the duration of exposure and reduce drug resistance. The objective of this study was to evaluate whether extended infusion of antipseudomonal beta-lactams improves mortality and clinical efficacy. Methods: Two independent authors identified eligible trials by searching the PubMed, Cochrane Library, Scopus, and ICHUSHI databases, in both English and Japanese, up to June 2019. Data were extracted from both randomized controlled and observational trials comparing extended infusion (>= 3 h) with intermittent infusion in critically ill patients. The primary outcome was all-cause mortality. Risk differences (RD) and 95% confidential intervals (CI) were calculated using a random-effects model and subgroup analyses were performed. Sensitivity and heterogeneity were also evaluated. Results: Nine studies involving 1508 participants were included in the meta-analysis. Mortality was lower for extended infusion than for intermittent infusion (RD -0.10; 95% CI -0.15 to -0.04). However, no significant between-group differences in clinical success, length of ICU stay, length of hospital stay, and antibiotic duration were observed. Conclusions: Extended infusions of beta-lactams were associated with reduced mortality rates but not with clinical success. (C) 2020 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据